Home > Internet > One Particular Voxtalisib All The Visitors Is Preaching About

One Particular Voxtalisib All The Visitors Is Preaching About

Added: (Wed Oct 10 2018)

Pressbox (Press Release) - Patients enrolled in protocols ALL/SHOP-94 and ALL/SHOP-99, from February 1994 to March 2005 received a similar chemotherapy protocol without imatinib and constitute the historical control group. Patients treated according protocols ALL/SHOP-94 and ALL/SHOP-99 were analysed together and had no differences in clinical characteristics at presentation and no significant differences in outcome. Pre-treatment evaluations included clinical history and physical examination, complete blood count with differential, bone marrow aspiration for cytology, flow cytometry, cytogenetic and molecular studies and cytological study of cerebrospinal fluid. Immunophenotypic study of blast population by flow cytometry was performed in bone marrow and/or peripheral blood samples CASK at diagnosis. In protocol ALL/SHOP-2005 flow cytometry was also used for detection of minimal residual disease (MRD) in all patients at different time points. The MRD studies were performed at the site of diagnosis and were not centralized. Bone marrow samples were studied at the site of diagnosis with standard banding techniques at diagnosis and follow-up. Karyotypes were classified according to the International System for Human Cytogenetic Nomenclature (Mitelman, 1995). BCR-ABL1 fusion gene was screened at diagnosis with the fluorescence in situ hybridization (FISH) technique in cases in PI3K inhibitor which no metaphases were obtained or as an initial screening method for the presence of the BCR-ABL1 rearrangement in some centres. Qualitative and quantitative RT-PCR for BCR-ABL1 transcript detection was performed on bone marrow samples at diagnosis according to the guidelines established by the Europe Against Cancer Programme (van Dongen et?al, 1999; Gabert et?al, 2003). In ALL/SHOP-2005 protocol, quantitative RT-PCR was recommended for detection of MRD at the time points described below. These studies were not centralized but performed in several reference laboratories in which national quality control programmes were implemented on a regular click here basis. Response evaluation as assessed by morphology was performed on day-15 bone marrow and at the end of induction. Good and poor early responses were defined by less or more than 5% of blasts on day-15 bone marrow, respectively. CR was defined by <5% blasts with normal cellularity on bone marrow smears, normal peripheral blood cell counts and no evidence of extramedullary disease. In protocol ALL/SHOP 2005, bone marrow aspirates with assessment of MRD by flow cytometry and/or quantitative RT-PCR were performed at the end of induction, at the beginning of consolidation block A and prior to HSCT. ALL/SHOP-94, ALL/SHOP-99 and ALL/SHOP 2005 were three consecutive treatment protocols conducted by SHOP (SEHOP).

Submitted by:
Disclaimer: Pressbox disclaims any inaccuracies in the content contained in these releases. If you would like a release removed please send an email to remove@pressbox.co.uk together with the url of the release.